Ian Hirsch

9.3k total citations
41 papers, 1.1k citations indexed

About

Ian Hirsch is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ian Hirsch has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Physiology, 16 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Ian Hirsch's work include Asthma and respiratory diseases (32 papers), Respiratory and Cough-Related Research (12 papers) and Eosinophilic Esophagitis (10 papers). Ian Hirsch is often cited by papers focused on Asthma and respiratory diseases (32 papers), Respiratory and Cough-Related Research (12 papers) and Eosinophilic Esophagitis (10 papers). Ian Hirsch collaborates with scholars based in United States, United Kingdom and Spain. Ian Hirsch's co-authors include Paul Newbold, Mitchell Goldman, James Zangrilli, Andrew Menzies‐Gow, Eugene R. Bleecker, J. Mark FitzGerald, Frank Trudo, Paul Metcalfe, Bradley E. Chipps and Xiao Xu and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and European Respiratory Journal.

In The Last Decade

Ian Hirsch

40 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ian Hirsch United States 15 790 607 196 193 162 41 1.1k
BL Barber United States 6 279 0.4× 268 0.4× 71 0.4× 59 0.3× 22 0.1× 15 482
Sherif Gonem United Kingdom 14 499 0.6× 468 0.8× 93 0.5× 75 0.4× 118 0.7× 35 753
Joanna Ling Singapore 10 351 0.4× 325 0.5× 63 0.3× 61 0.3× 38 0.2× 17 582
Alessandro Sanduzzi Italy 7 133 0.2× 106 0.2× 74 0.4× 55 0.3× 81 0.5× 10 444
Hubert Méchin France 8 325 0.4× 101 0.2× 54 0.3× 327 1.7× 9 0.1× 17 504
Eleanor J. Hothersall United Kingdom 11 210 0.3× 175 0.3× 138 0.7× 16 0.1× 43 0.3× 20 827
Vicky Thomas United Kingdom 9 109 0.1× 136 0.2× 25 0.1× 19 0.1× 21 0.1× 21 366
Lieven Nils Kennes Germany 12 84 0.1× 66 0.1× 93 0.5× 11 0.1× 6 0.0× 41 435
Rebecca Hahn United States 9 98 0.1× 69 0.1× 49 0.3× 8 0.0× 25 0.2× 16 508
Jennifer Colby United States 11 83 0.1× 145 0.2× 40 0.2× 8 0.0× 10 0.1× 33 400

Countries citing papers authored by Ian Hirsch

Since Specialization
Citations

This map shows the geographic impact of Ian Hirsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Hirsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Hirsch more than expected).

Fields of papers citing papers by Ian Hirsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Hirsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Hirsch. The network helps show where Ian Hirsch may publish in the future.

Co-authorship network of co-authors of Ian Hirsch

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Hirsch. A scholar is included among the top collaborators of Ian Hirsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Hirsch. Ian Hirsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Xingnan, Paul Newbold, Rohit Katial, et al.. (2024). Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness. The Journal of Allergy and Clinical Immunology In Practice. 12(10). 2732–2743. 4 indexed citations
2.
Moore, Mia, Ian Hirsch, Tom White, et al.. (2024). Estimating vaccine efficacy during open-label follow-up of COVID-19 vaccine trials based on population-level surveillance data. Epidemics. 47. 100768–100768.
3.
Bleecker, Eugene R., Deborah A. Meyers, Dean Billheimer, et al.. (2023). Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma. The Journal of Allergy and Clinical Immunology In Practice. 11(6). 1805–1813. 11 indexed citations
4.
Jackson, David J., Hassan Burhan, Andrew Menzies‐Gow, et al.. (2022). Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use. The Journal of Allergy and Clinical Immunology In Practice. 10(6). 1534–1544.e4. 30 indexed citations
5.
6.
Kraft, Monica, Guy Brusselle, J. Mark FitzGerald, et al.. (2021). Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. European Respiratory Journal. 58(6). 2100413–2100413. 43 indexed citations
7.
Lugogo, Njira, et al.. (2020). Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Annals of Allergy Asthma & Immunology. 125(2). 171–176. 18 indexed citations
8.
9.
Chipps, Bradley E., Ian Hirsch, Frank Trudo, Marianna Alacqua, & James Zangrilli. (2019). Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Annals of Allergy Asthma & Immunology. 124(1). 79–86. 29 indexed citations
10.
Chupp, Geoffrey, Njira Lugogo, Joel N. Kline, et al.. (2019). Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Annals of Allergy Asthma & Immunology. 122(5). 478–485. 12 indexed citations
11.
O’Quinn, Sean, Xiao Xu, & Ian Hirsch. (2019). <p>Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma</p>. Journal of Asthma and Allergy. Volume 12. 21–33. 13 indexed citations
12.
Jackson, David J., Marc Humbert, Ian Hirsch, Paul Newbold, & Esther García Gil. (2019). Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Advances in Therapy. 37(2). 718–729. 51 indexed citations
13.
Bleecker, Eugene R., Michael E. Wechsler, J. Mark FitzGerald, et al.. (2018). Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. European Respiratory Journal. 52(4). 1800936–1800936. 172 indexed citations
14.
Chipps, Bradley E., Paul Newbold, Ian Hirsch, Frank Trudo, & Mitchell Goldman. (2018). Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Annals of Allergy Asthma & Immunology. 120(5). 504–511.e4. 87 indexed citations
15.
Wenzel, Sally E., et al.. (2018). Benralizumab efficacy in patients with uncontrolled eosinophilic asthma by age at diagnosis. PA603–PA603. 1 indexed citations
16.
FitzGerald, J. Mark, Eugene R. Bleecker, Andrew Menzies‐Gow, et al.. (2017). Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. The Lancet Respiratory Medicine. 6(1). 51–64. 225 indexed citations
17.
Mt‐Isa, Shahrul, Mario Ouwens, Véronique Robert, et al.. (2015). Structured Benefit–risk assessment: a review of key publications and initiatives on frameworks and methodologies. Pharmaceutical Statistics. 15(4). 324–332. 30 indexed citations
18.
19.
Chuang‐Stein, Christy, Simon Kirby, Ian Hirsch, & Gary Atkinson. (2010). The role of the minimum clinically important difference and its impact on designing a trial. Pharmaceutical Statistics. 10(3). 250–256. 40 indexed citations
20.
Arnold, Lesley M., Krai Chatamra, Ian Hirsch, & Malcolm Stoker. (2010). Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clinical Therapeutics. 32(9). 1618–1632. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by BL Barber Breakdown of academic impact, for papers by Sherif Gonem Breakdown of academic impact, for papers by Joanna Ling Breakdown of academic impact, for papers by Alessandro Sanduzzi Breakdown of academic impact, for papers by Hubert Méchin Breakdown of academic impact, for papers by Eleanor J. Hothersall Breakdown of academic impact, for papers by Vicky Thomas Breakdown of academic impact, for papers by Lieven Nils Kennes Breakdown of academic impact, for papers by Rebecca Hahn Breakdown of academic impact, for papers by Jennifer Colby
Rankless by CCL
2026